Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erbaiyin granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Affiliated Hospital of Changchun University of Traditional Chinese Medicine. It is specifically formulated to treat drug-resistant bacterial diarrhea, particularly cases associated with multi-drug resistant (MDR) pathogens such as carbapenem-resistant Enterobacteriaceae (CRE). The preparation is designed to clear heat, detoxify, and resolve dampness, which corresponds to its pharmacological actions of inhibiting bacterial growth, reducing intestinal inflammation, and regulating gut microbiota. Clinical and preclinical research suggests that Erbaiyin granule can help restore the intestinal mucosal barrier and improve the clinical symptoms of patients suffering from refractory infectious diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Erbaiyin granule.